<- Go Home

Vimian Group AB (publ)

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Market Cap

SEK 1.5B

Volume

439.3K

Cash and Equivalents

SEK 50.4M

EBITDA

SEK 104.9M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

SEK 299.2M

Profit Margin

69.00%

52 Week High

SEK 3.95

52 Week Low

SEK 2.19

Dividend

N/A

Price / Book Value

2.01

Price / Earnings

39.33

Price / Tangible Book Value

-10.37

Enterprise Value

SEK 1.7B

Enterprise Value / EBITDA

15.51

Operating Income

SEK 73.3M

Return on Equity

5.29%

Return on Assets

4.06

Cash and Short Term Investments

SEK 50.4M

Debt

SEK 247.8M

Equity

SEK 730.0M

Revenue

SEK 433.6M

Unlevered FCF

SEK 66.6M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches